Improving the efficacy of antibody-based cancer therapies
P Carter - Nature Reviews Cancer, 2001 - nature.com
Nature Reviews Cancer, 2001•nature.com
A quarter of a century after their advent, monoclonal antibodies have become the most
rapidly expanding class of pharmaceuticals for treating a wide variety of human diseases,
including cancer. Although antibodies have yet to achieve the ultimate goal of curing cancer,
many innovative approaches stand poised to improve the efficacy of antibody-based
therapies.
rapidly expanding class of pharmaceuticals for treating a wide variety of human diseases,
including cancer. Although antibodies have yet to achieve the ultimate goal of curing cancer,
many innovative approaches stand poised to improve the efficacy of antibody-based
therapies.
Abstract
A quarter of a century after their advent, monoclonal antibodies have become the most rapidly expanding class of pharmaceuticals for treating a wide variety of human diseases, including cancer. Although antibodies have yet to achieve the ultimate goal of curing cancer, many innovative approaches stand poised to improve the efficacy of antibody-based therapies.
nature.com